Nausea News and Research

RSS

Nausea is the sensation of unease and discomfort in the upper stomach and head with an urge to vomit. An attack of nausea is known as a qualm.

USPTO rejects MonoSol's patent infringement claims against BDSI

The United States Patent & Trademark Office has informed BioDelivery Sciences International, Inc. that it has rejected all claims by MonoSol Rx, LLC (MonoSol) in its US Patent No. 7,425,292 (the '292 Patent) which is currently being asserted against BDSI and its commercial partners for ONSOLIS.

23 Feb 2012

Varenicline improves walking ability in patients with SCA3

A nicotinic drug approved for smoking cessation significantly improved the walking ability of patients suffering from an inherited form of ataxia, reports a new clinical study led by University of South Florida researchers.

23 Feb 2012

Gluten-free diet more of a fad than absolute necessity for many

Many people claim that gluten sensitivity is on the rise and consequently gluten-free products are more popular than ever. A study explores whether shunning gluten is really necessary and finds that in most cases it is not.

22 Feb 2012

Silent & atypical heart attacks more dangerous & fatal in young women

It is known that chest pain or discomfort is the most common heart attack symptom. In addition, fatigue, nausea, shortness of breath and pain or numbness in the jaw, arms or back can also signal a blocked artery cutting off vital oxygen and nutrients from the heart.

22 Feb 2012

EC approves Plexxikon's Zelboraf to treat BRAF mutation-positive MM

Plexxikon Inc., a member of Daiichi Sankyo Group, today announced that the European Commission has approved Zelboraf (vemurafenib) for the monotherapy treatment of adult patients with BRAFV600 mutation-positive unresectable or metastatic melanoma.

20 Feb 2012

Modified imatinib cancer drug prevents morphine tolerance in rats

By reformulating the common cancer drug imatinib (Gleevec), researchers have eliminated morphine tolerance in rats - an important step toward improving the effectiveness of chronic pain management in patients, according to researchers at The University of Texas MD Anderson Cancer Center.

20 Feb 2012

Botox efficacy uncertain in treating migraine says NICE

Botox – used as an anti-wrinkle agent - is unlikely to be recommended for the treatment of chronic migraines on the NHS in England and Wales. According to the National Institute for Health and Clinical Excellence (NICE) draft guidelines there is insufficient evidence that it works.

18 Feb 2012

Norovirus outbreak at the George Washington University campus

Officials at the university and the District of Columbia's Health Department confirmed 85 cases of the gastrointestinal illness were diagnosed since Monday. The virus was found in locations including the central Foggy Bottom campus and the Mount Vernon campus in Northwest Washington. Members of the university also reported cases off campus.

18 Feb 2012

Common misconceptions about brain and severity of head injuries

According to the Centers for Disease Control, sports-related concussions are an epidemic in this country. With more than three million sports-related concussions happening every year, research shows the effects can be long-lasting, even leading to permanent brain damage and early onset of dementia. Dr. Howard Derman, director of the Methodist Concussion Center in Houston, shares some of the common misconceptions about the brain and the severity of head injuries.

18 Feb 2012

Corcept receives FDA approval for Korlym to treat endogenous Cushing's syndrome

Today, Korlym (mifepristone) was approved by the U.S. Food and Drug Administration to control high blood sugar levels (hyperglycemia) in adults with endogenous Cushing's syndrome.

18 Feb 2012

BYETTA-basal insulin combination therapy receives EMA CHMP positive opinion

Amylin Pharmaceuticals, Inc. and Eli Lilly and Company today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has issued a positive opinion in the European Union for the expanded use of BYETTA (exenatide twice-daily) as an add-on therapy to basal insulin, with or without metformin and/or Actos (pioglitazone), for the treatment of type 2 diabetes in adults who have not achieved adequate glycemic control with these agents.

17 Feb 2012

Nordion celebrates first anniversary of market launch of TheraSphere

Nordion Inc., a leading provider of products and services to the global health science market, today celebrated the first anniversary of the market introduction of TheraSphere, an innovative radioembolic liver cancer therapy, in the Republic of Turkey.

17 Feb 2012

AstraZeneca launches ARIMIDEX Direct to help cancer patients

AstraZeneca today announced its first-ever direct-to-patient program offering patients with a valid prescription for ARIMIDEX or anastrozole the opportunity to have the brand ARIMIDEX delivered directly to their home by Express Scripts, a specialty pharmacy services provider, for $40 per month, including shipping.

17 Feb 2012

Pfizer, Mylan enter settlement agreement to resolve e-cue patent litigation

Mylan Inc. and Pfizer Inc. today announced that Meridian Medical Technologies, a Pfizer subsidiary, has entered into a settlement agreement with Intelliject and Sanofi-Aventis that will resolve pending patent litigation related to Intelliject's 505(b)(2) new drug application (NDA) for its epinephrine auto-injector known as e-cue, which will be manufactured and marketed by Sanofi-Aventis.

16 Feb 2012

Acorda's fourth quarter GAAP net income increases to $12.7 million

Acorda Therapeutics, Inc. today announced its financial results for the fourth quarter and full year ended December 31, 2011.

16 Feb 2012

Valeant receives FDA approval for secondary supplier of Methoxsalen

The FDA has approved the addition of a secondary supplier of Methoxsalen USP, an integral component of a treatment for the relief of moderate to severe psoriasis prescribed under the brand name Oxsoralen-Ultra (methoxsalen) Capsules, USP, 10mg.

15 Feb 2012

Incidence of TBI likely greater than previously estimated

Though researchers are becoming increasingly aware of the long-term effects of head injury, few studies have looked at the prevalence of traumatic brain injury (TBI) in all age groups, including males and females, taking into account both mild and serious events. In a recent study published in Epidemiology, Mayo Clinic researchers applied a new, refined system for classifying injuries caused by force to the head and found that the incidence of traumatic brain injury is likely greater than has been estimated by the Centers for Disease Control and Prevention.

15 Feb 2012

Penn State researchers develop new app for caffeine drinkers

Caffeinated drinks such as coffee and soda are the pick-me-ups of choice for many people, but too much caffeine can cause nervousness and sleep problems.

14 Feb 2012

Preliminary results from Soligenix SGX201 Phase 1/2 trial on acute radiation enteritis

Soligenix, Inc., a development stage biopharmaceutical company, announced preliminary results today from a Phase 1/2 clinical trial evaluating SGX201, a time-release formulation of oral beclomethasone 17,21-dipropionate (oral BDP), for the prevention of acute radiation enteritis.

10 Feb 2012

Now on stands - Inhaled caffeine

A Harvard professor has come up with a device that helps people inhale their caffeine from a lipstick-sized tube. Critics say the novel product, called “AeroShot,” is not without its risks. The product went on the market late last month in Massachusetts and New York, and is also available in France. A single unit costs $2.99 at convenience, mom-and-pop, liquor and online stores.

9 Feb 2012